Sutro Biopharma, Inc. (STRO) has a consensus analyst rating of Buy, based on 19 analysts covering the stock. Of those, 16 recommend buying, 2 recommend holding, and 1 recommend selling.
The analyst consensus price target for STRO is $9.86, representing a -66.9% downside from the current price of $29.77. Price targets range from a low of $2.00 to a high of $15.00.
